Replies to post #69751 on Biotech Values

[rkrw]

Could well be other low hanging fruits. I do think a suite of products is probably a good thing since you can bundle price.

I assume part of your argument is commentary in favor of mnta. We know mnta has characterized and filed on lovenox and copaxone. But we don't know what else mnta is on a filing track for if anything.